$XBI $67.40 | -3.91%
Table of Contents:
Covid Updates
$
Pipeline Updates
$ARDX -5.9% Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults source
$AGEN -8.3% Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab. source
$ORMP -5.2% Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes. source
$ALPN +0.5% Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab. source
$QURE +6.3% uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review. source
$HZNP +0.7% Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology. source
$AERI -8.4% Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease. source
$OCGN -5.0% Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition. source
$ALDX -5.0% Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Source
$SYBX -7.4% Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria. source
$SWTX -11.4% SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors. source
$MNKD -4.1% MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™. source
$AMPH -2.5% Amphastar Receives FDA Approval for Regadenoson. source
$UTHR +4.2% United Therapeutics Announces FDA Approval of Tyvaso DPIâ„¢. source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$KDNY +2.3% CHINOOK THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING source
$CASI +9.3% Casi Pharmaceuticals Enteres Into Sublicense Agreement With Tianshi Pharmaceuticals For Anti-cd38 Monoclonal Antibody (Mab) Cid-103 In Autoimmune Field source
$HALO +1.1% Halozyme Completes Antares Pharma Acquisition. source
$DERM +4.5% Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity. source
Posted by JM/FS